China Earmarks RMB 300 Million For H7N9 Flu Monitoring
This article was originally published in PharmAsia News
The Chinese government recently earmarked over RMB 300 million ($48 million) for monitoring of influenza and new types of pneumonia, particularly H7N9 flu and severe acute respiratory syndromes.
You may also be interested in...
A nasal spray formulated using compounds already approved by regulatory bodies in Europe and the US can “prevent and slow” transmission of COVID-19, according to UK researchers who are now seeking a partner to commercialize the product.
Russia is promising the best of both worlds – a low price with a near-perfect efficacy. While the basic science is plausible, its best-in-class claims are bound to generate skepticism.
The Belgian biotech has divested its drug discovery services unit in Croatia which was making a nice profit but was not a priority as Galapagos concentrates on setting up its commercial operations in Europe.